GSK's battle to win over the $2 billion market for cervical cancer vaccines has experienced a few big setbacks. French health officials are now recommending against paying for Cervarix and the FDA has lingered long over GSK's application for approval. But Glaxo U.S. pharma chief Chris Viehbacher [1] (photo [2]) insists in a talk with the Wall Street Journal that all is well. Viehbacher says that at the end of the day, head-to-head study data [3] will prove too compelling for the regulators on both sides of the Atlantic to ignore. Meanwhile, though, Merck's Gardasil continues to solidify its position in the market.

- read the report [4] in the Wall Street Journal

Related Articles:
GSK hit with Cervarix application delay [5]
It's Merck v. Glaxo in vaccine battle [6]
GSK prepares to go head-to-head with Merck [7]